Table 3.
Secondary Outcomes by Sex
| Outcomes | Sex | Pooled Effect Sizes |
|||||
|---|---|---|---|---|---|---|---|
| 1,500-3,000 MET-min/wk |
>3,000 MET-min/wk |
||||||
| No. of Studies | Mean Difference (95% CI) | Heterogeneity (I2, P Value) | No. of Studies | Mean Difference (95% CI) | Heterogeneity (I2, P Value) | ||
| No. of calcified plaques per patients | Males | 2 | −0.03 (−0.87 to 0.81, P = 0.95) | (94.87%, P < 0.001) | 2 | 0.82 (−0.14 to 1.78, P = 0.09) | (92.45%, P < 0.001) |
| Females | 2 | −0.24 (−0.51 to 0.04, P = 0.09) | (85.63%, P < 0.001) | 2 | −0.26 (−0.42 to −0.1, P < 0.001) | (0%, P = 0.28) | |
| Calcified lesions volume | Males | 1 | −16.23 (−27.56 to −4.9, P < 0.001) | – | 2 | 26.91 (12.06-41.76, P < 0.001) | (0%, P = 0.32) |
| Females | 1 | −10.75 (−16.52 to −4.98, P < 0.001) | – | 2 | −16.89 (−38.17 to 4.39, P = 0.12) | (29.18%, P = 0.16) | |
| Calcified plaques | Males | 1 | OR 1.52 (0.96-2.42, P = 0.07) | – | 2 | OR 2.31 (0.67-7.98, P = 0.19) | (87.42%, P < 0.001) |
| Females | – | – | – | – | – | – | |
Abbreviations as in Table 1.